The cutaneous epidermal growth factor network: Can it be translated clinically to stimulate hair growth?
The influences exerted by the epidermal growth factor receptor (EGFR) on the skin act at multiple levels, which involve compartments that normally express EGFR. These include the basal and suprabasal layers of the epidermis, sebaceous glands, and the outer root sheath of the hair follicles. The physiological roles of EGFR ensure epidermal renewal and integrity, along with a gatekeeping and function and hair growth stimulation functions. Important cellular functions that are altered during EGF receptor blocking therapy consist of epidermal differentiation, proliferation, apoptosis, and migration, with an overall dominating effect of inducing growth arrest and terminal differentiation of the keratinocytes in the basal layers. The effects of EGFR blockage on the hair cycle include terminal differentiation of the hair follicle, which in certain cases may be associated with trichomegaly. Trichomegaly of the eyelashes may occur as an isolated occurrence or, frequently, as part of a generalized phenomenon that may be associated with the use of the EGFR inhibitors. Molecular changes associated with EGFR blockage are discussed, relevant to their association with hair growth. Modulation of Akt, AP2alpha, CDK4, Notch-1, p27KIP1, and Hedgehog expression are involved in the initiation of the hair cycle and inducement of the anagen phase, followed by proliferation and differentiation of the hair follicles. Epidermal growth factor receptor inhibitors have been developed as therapeutic molecules directed against cancer; in these regimens the knowledge of EGF receptor signaling functions has been translated into significant clinical results. However, among their various collateral effects on the skin, hair growth is observed to occur in certain patients. A particular "wavy" hair phenotype is observed during the pharmacological EGFR receptor blockade, just as in murine transgenic models that carry loss of function of TGF-alpha or EGFR genes. A better characterization of the individual roles pertaining to the EGF family ligands and receptors, has the potential provide new strategies for the management of hair loss.
Alexandrescu
Doru T
DT
Georgetown Dermatology, Washington, DC, USA. mddoru@hotmail.com
Kauffman
C Lisa
CL
Dasanu
Constantin A
CA
D000505:Alopecia / Q000628:therapy*; D000818:Animals; D000875:Anthralin / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D035843:Biomedical Research; D015510:Clinical Medicine; D051358:Cyclin-Dependent Kinase 4 / Q000502:physiology; D050760:Cyclin-Dependent Kinase Inhibitor p27; D004815:Epidermal Growth Factor / Q000494:pharmacology / Q000502:physiology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000502:physiology*; D005128:Eye Diseases / Q000150:complications / Q000503:physiopathology; D006197:Hair / Q000002:abnormalities / Q000254:growth & development; D018859:Hair Follicle / Q000502:physiology; D053823:Hedgehog Proteins / Q000502:physiology; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000032:analysis / Q000502:physiology; D051379:Mice; D005810:Multigene Family; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology; D051880:Receptors, Notch / Q000502:physiology; D015398:Signal Transduction; D050656:Transcription Factor AP-2 / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000172:deficiency / Q000235:genetics
D000970:Antineoplastic Agents; C436291:CDKN1B protein, human; D053823:Hedgehog Proteins; D047908:Intracellular Signaling Peptides and Proteins; D051880:Receptors, Notch; D050656:Transcription Factor AP-2; D014409:Tumor Necrosis Factor-alpha; D050760:Cyclin-Dependent Kinase Inhibitor p27; D004815:Epidermal Growth Factor; C512478:EGFR protein, human; C541485:EGFR protein, mouse; D066246:ErbB Receptors; C514862:Akt1 protein, mouse; D051057:Proto-Oncogene Proteins c-akt; D051358:Cyclin-Dependent Kinase 4; D000875:Anthralin